339 related articles for article (PubMed ID: 36611808)
21. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline.
Lan G; Du J; Chen X; Wang Q; ; Han Y; Guo T
Neurobiol Aging; 2023 Dec; 132():209-219. PubMed ID: 37852045
[TBL] [Abstract][Full Text] [Related]
22. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
23. An Efficient Combination among sMRI, CSF, Cognitive Score, and
Khatri U; Kwon GR
Comput Intell Neurosci; 2020; 2020():8015156. PubMed ID: 32565773
[TBL] [Abstract][Full Text] [Related]
24. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
25. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
Wang S; Zhang J; Pan T;
Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
[TBL] [Abstract][Full Text] [Related]
26. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study.
Ten Kate M; Redolfi A; Peira E; Bos I; Vos SJ; Vandenberghe R; Gabel S; Schaeverbeke J; Scheltens P; Blin O; Richardson JC; Bordet R; Wallin A; Eckerstrom C; Molinuevo JL; Engelborghs S; Van Broeckhoven C; Martinez-Lage P; Popp J; Tsolaki M; Verhey FRJ; Baird AL; Legido-Quigley C; Bertram L; Dobricic V; Zetterberg H; Lovestone S; Streffer J; Bianchetti S; Novak GP; Revillard J; Gordon MF; Xie Z; Wottschel V; Frisoni G; Visser PJ; Barkhof F
Alzheimers Res Ther; 2018 Sep; 10(1):100. PubMed ID: 30261928
[TBL] [Abstract][Full Text] [Related]
27. Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment.
Pyun JM; Park YH; Lee KJ; Kim S; Saykin AJ; Nho K;
Transl Neurodegener; 2021 Aug; 10(1):32. PubMed ID: 34465370
[TBL] [Abstract][Full Text] [Related]
28. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in the association of APOE ε4 genotype with longitudinal hippocampal atrophy in cognitively normal older people.
Shen S; Zhou W; Chen X; Zhang J;
Eur J Neurol; 2019 Nov; 26(11):1362-1369. PubMed ID: 31102429
[TBL] [Abstract][Full Text] [Related]
30. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
Löwe LC; Gaser C; Franke K;
PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.
Lu Y;
Aging Clin Exp Res; 2022 Oct; 34(10):2399-2406. PubMed ID: 35988117
[TBL] [Abstract][Full Text] [Related]
32. APOE ε4 increases the risk of progression from amnestic mild cognitive impairment to Alzheimer's disease among ethnic Chinese in Taiwan.
Wang PN; Hong CJ; Lin KN; Liu HC; Chen WT
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):165-9. PubMed ID: 20660919
[TBL] [Abstract][Full Text] [Related]
33. Association of cerebrospinal fluid Neurogranin with Alzheimer's disease.
Wang L;
Aging Clin Exp Res; 2019 Feb; 31(2):185-191. PubMed ID: 29667155
[TBL] [Abstract][Full Text] [Related]
34. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
35. CSF GAP-43 as a biomarker of synaptic dysfunction is associated with tau pathology in Alzheimer's disease.
Qiang Q; Skudder-Hill L; Toyota T; Wei W; Adachi H
Sci Rep; 2022 Oct; 12(1):17392. PubMed ID: 36253408
[TBL] [Abstract][Full Text] [Related]
36. Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.
Suzuki K; Hirakawa A; Ihara R; Iwata A; Ishii K; Ikeuchi T; Sun CK; Donohue M; Iwatsubo T;
Alzheimers Dement (N Y); 2020; 6(1):e12007. PubMed ID: 32211510
[TBL] [Abstract][Full Text] [Related]
37. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
Zhang H; Lyu D; Jia J;
J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
[TBL] [Abstract][Full Text] [Related]
38. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
39. Predicting the apolipoprotein E ε4 allele carrier status based on gray matter volumes and cognitive function.
Kim HG; Tian Y; Jung SM; Park S; Rhee HY; Ryu CW; Jahng GH
Brain Behav; 2024 Jan; 14(1):e3381. PubMed ID: 38376028
[TBL] [Abstract][Full Text] [Related]
40. Role of nerve growth factor on cognitive impairment in patients with Alzheimer's disease carrying apolipoprotein E ε4.
He M; Liu Z; Lian T; Guo P; Zhang W; Huang Y; Zhang Y; Liu G; Zhang W; Li J; Guan H; Zhang W; Luo D; Qi J; Yue H; Wang X; Zhang W
CNS Neurosci Ther; 2024 Jun; 30(6):e14560. PubMed ID: 38112032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
